Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Drug Hypersensitivity Reactions and Pseudoallergy: A Moving Frontline in Allergy...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Drug Hypersensitivity Reactions and Pseudoallergy: A Moving Frontline in Allergy Research

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 13378

Special Issue Editor

Dr. János Szebeni

E-Mail Website
Guest Editor
Nanomedicine Research and Education Center, Semmelweis University, 1089 Budapest, Hungary
Interests: hypersensitvity reactions; anaphylaxis; pseudoanaphylaxis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Pseudo-allergy is an acute allergy syndrome manifesting itself in the same clinical symptoms as allergy, but the reactions are not IgE-mediated. In addition to the nonimmune-mediated release of mediators from mast cells and/or basophils, a frequent cause of pseudo-allergy is IgG and IgM binding to the allergen with subsequent complement activation and stimulation of allergy-mediating immune cells via anaphylatoxin and other surface receptors. Pseudo-allergy has become a major issue in modern pharmacotherapy, as the number of unpredicted pseudo-allergic hypersensitivity reactions to state-of-art biologicals and nanomedicines far outweigh the occurrence of true allergic reactions, which can be predicted and diagnosed by classic allergy tests. At present, the standard care against pseudo-allergy, whose worst manifestation is life-threatening pseudo-anaphylaxis, is premedication of patients with antihistamines, steroids, and non-steroidal anti-inflammatory agents. However, this therapy is frequently ineffective, presenting a clinical need for better prevention and/or treatment protocols. A recent development in this field is that the increased occurrence of allergic reactions to some COVID-19 vaccines actually represent a pseudo-allergy. This volume provides a collections of original research papers and reviews on these poorly understood acute reactions, written by clinicians and immunologists encountering this problem. Since IJMS is a journal of molecular science, pure clinical studies will not suitable for our journal. However, clinical or pure model submissions with biomolecular experiments are welcomed.

Dr. János Szebeni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Ig-E-mediated allergy
  • type-I allergy
  • antibodies complement
  • CARPA
  • mast cells
  • histamine
  • IgG
  • IgM
  • IgE
  • hypersensitvity reactions
  • anaphylaxis
  • pseudo-anaphylaxis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2483 KiB  
Article
mRNA-LNP COVID-19 Vaccine Lipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions
by Tamás Bakos, Tamás Mészáros, Gergely Tibor Kozma, Petra Berényi, Réka Facskó, Henriette Farkas, László Dézsi, Carlo Heirman, Stefaan de Koker, Raymond Schiffelers, Kathryn Anne Glatter, Tamás Radovits, Gábor Szénási and János Szebeni
Int. J. Mol. Sci. 2024, 25(7), 3595; https://doi.org/10.3390/ijms25073595 - 22 Mar 2024
Cited by 11 | Viewed by 9787
Abstract
A small fraction of people vaccinated with mRNA–lipid nanoparticle (mRNA-LNP)-based COVID-19 vaccines display acute or subacute inflammatory symptoms whose mechanism has not been clarified to date. To better understand the molecular mechanism of these adverse events (AEs), here, we analyzed in vitro the [...] Read more.
A small fraction of people vaccinated with mRNA–lipid nanoparticle (mRNA-LNP)-based COVID-19 vaccines display acute or subacute inflammatory symptoms whose mechanism has not been clarified to date. To better understand the molecular mechanism of these adverse events (AEs), here, we analyzed in vitro the vaccine-induced induction and interrelations of the following two major inflammatory processes: complement (C) activation and release of proinflammatory cytokines. Incubation of Pfizer-BioNTech’s Comirnaty and Moderna’s Spikevax with 75% human serum led to significant increases in C5a, sC5b-9, and Bb but not C4d, indicating C activation mainly via the alternative pathway. Control PEGylated liposomes (Doxebo) also induced C activation, but, on a weight basis, it was ~5 times less effective than that of Comirnaty. Viral or synthetic naked mRNAs had no C-activating effects. In peripheral blood mononuclear cell (PBMC) cultures supplemented with 20% autologous serum, besides C activation, Comirnaty induced the secretion of proinflammatory cytokines in the following order: IL-1α < IFN-γ < IL-1β < TNF-α < IL-6 < IL-8. Heat-inactivation of C in serum prevented a rise in IL-1α, IL-1β, and TNF-α, suggesting C-dependence of these cytokines’ induction, although the C5 blocker Soliris and C1 inhibitor Berinert, which effectively inhibited C activation in both systems, did not suppress the release of any cytokines. These findings suggest that the inflammatory AEs of mRNA-LNP vaccines are due, at least in part, to stimulation of both arms of the innate immune system, whereupon C activation may be causally involved in the induction of some, but not all, inflammatory cytokines. Thus, the pharmacological attenuation of inflammatory AEs may not be achieved via monotherapy with the tested C inhibitors; efficacy may require combination therapy with different C inhibitors and/or other anti-inflammatory agents. Full article
(This article belongs to the Special Issue Drug Hypersensitivity Reactions and Pseudoallergy: A Moving Frontline in Allergy Research)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 478 KiB  
Review
Balancing Benefits and Risks: A Literature Review on Hypersensitivity Reactions to Human G-CSF (Granulocyte Colony-Stimulating Factor)
by Roxana Silvia Bumbăcea, Mihaela Ruxandra Udrea, Selda Ali and Violeta Claudia Bojincă
Int. J. Mol. Sci. 2024, 25(9), 4807; https://doi.org/10.3390/ijms25094807 - 28 Apr 2024
Cited by 6 | Viewed by 2383
Abstract
Human granulocyte colony-stimulating factor (G-CSF) is a granulopoietic growth factor used in the treatment of neutropenia following chemotherapy, myeloablative treatment, or healthy donors preparing for allogeneic transplantation. Few hypersensitivity reactions (HRs) have been reported, and its true prevalence is unknown. We aimed to [...] Read more.
Human granulocyte colony-stimulating factor (G-CSF) is a granulopoietic growth factor used in the treatment of neutropenia following chemotherapy, myeloablative treatment, or healthy donors preparing for allogeneic transplantation. Few hypersensitivity reactions (HRs) have been reported, and its true prevalence is unknown. We aimed to systematically characterize G-CSF-induced HRs while including a comprehensive list of adverse reactions. We reviewed articles published before January 2024 by searching in the PubMed, Embase, Cochrane Library, and Web of Science databases using a combination of the keywords listed, selected the ones needed, and extracted relevant data. The search resulted in 68 entries, 17 relevant to our study and 7 others found from manually searching bibliographic sources. A total of 40 cases of G-CSF-induced HR were described and classified as immediate (29) or delayed (11). Immediate ones were mostly caused by filgrastim (13 minimum), with at least 9 being grade 5 on the WAO anaphylaxis scale. Delayed reactions were mostly maculopapular exanthemas and allowed for the continuation of G-CSF. Reactions after first exposure frequently appeared and were present in at least 11 of the 40 cases. Only five desensitization protocols have been found concerning the topic at hand in the analyzed data. We believe this study brings to light the research interest in this topic that could benefit from further exploration, and propose regular updating to include the most recently published evidence. Full article
(This article belongs to the Special Issue Drug Hypersensitivity Reactions and Pseudoallergy: A Moving Frontline in Allergy Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop